(Q35687700)

9 August 2017

1 reference

title

Progress in the therapy of small cell lung cancer (English)

1 reference

9 August 2017

1 reference

Miklos Simon

1

1 reference

9 August 2017

Athanassios Argiris

series ordinal

2

1 reference

9 August 2017

John R Murren

series ordinal

3

1 reference

9 August 2017

language of work or name

1 reference

1 February 2004

1 reference

Critical Reviews in Oncology Hematology

9 August 2017

published in

1 reference

9 August 2017

volume

49

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

119-133

1 reference

New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Alkylating agents in bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Medical Research Council Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Topoisomerase I targeting agents in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Second-line chemotherapy for relapsed small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Clinical pharmacokinetics of topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Single-agent gemcitabine in patients with resistant small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Japan Lung Cancer Vinorelbine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A meta-analysis of thoracic radiotherapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

The role of radiation therapy in the treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a So

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Local failure in patients treated with radiotherapy and multidrug chemotherapy for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Intensity-modulated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

CNS metastases in small cell bronchogenic carcinoma.Increasing frequency and changing pattern with lengthening survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Prophylactic cranial irradiation and small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Is prophylactic cranial irradiation indicated in small-cell lung cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

The role of prophylactic brain irradiation in limited stage small cell lung cancer: clinical, neuropsychologic, and CT sequelae.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Prophylactic Cranial Irradiation for Patients With Small-Cell Lung Cancer in Complete Remission

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Escalating drug delivery in cancer chemotherapy: a review of concepts and practice--Part 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Treatment of limited small-cell lung cancer with concurrent etoposide/cisplatin and radiotherapy followed by intensification with high-dose cyclophosphamide: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Dose-intensive therapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Hematopoietic stem cell transplantation for small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Intensive combined modality therapy for limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Changing views of the role of matrix metalloproteinases in metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the Europea

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2803%2900118-5

7 January 2021

10.1016/S1040-8428(03)00118-5

Identifiers

DOI

1 reference

9 August 2017

1 reference